Although these new findings suggest GPR56 could be an interesting molecular target to mimic the molecular signaling related to exercise-induced clinical benefits, the expression profiles of GPR56 have not been reported in PAD animal models and patients with PAD. Here, ADGRG1 is linked to peripheral arterial disease.